Humatrope (Somatropin)

Humatrope is prescribed for a range of pediatric and adult endocrine disorders where growth hormone production is inadequate or absent, helping to promote normal growth and metabolic function.

• Children with confirmed growth hormone deficiency to support linear growth and improve body composition.
• Adults with growth hormone deficiency to increase lean body mass, reduce fat mass, and improve quality of life.
• Girls with Turner syndrome to enhance height velocity during growth therapy.
• Patients with chronic renal insufficiency experiencing growth failure to achieve age‑appropriate growth.
• Individuals with Prader‑Willi syndrome to improve growth and body composition.
• Children with idiopathic short stature when other causes have been excluded.

• Somatropin in Humatrope is a recombinant form of human growth hormone that binds to growth hormone receptors on target cells, primarily in liver, bone, and muscle. Receptor activation triggers the Janus kinase 2 (JAK2)–signal transducer and activator of transcription 5 (STAT5) pathway, leading to increased transcription of insulin‑like growth factor‑1 (IGF‑1) and other anabolic mediators. The cascade promotes protein synthesis, cell proliferation, and linear growth.

Adverse reactions to Humatrope vary in frequency and severity; they are reported in clinical studies and post‑marketing surveillance.

Common

• Injection site pain, redness, or swelling at the administration site.
• Headache, fatigue, or mild dizziness during the first weeks of therapy.
• Transient fluid retention leading to peripheral edema.
• Joint stiffness or mild arthralgia, especially in the knees and ankles.
• Nausea or abdominal discomfort, often transient during dose titration.

Serious

• Development of antibodies that neutralize somatropin, reducing efficacy and potentially causing allergic reactions.
• Intracranial hypertension presenting with headache, visual changes, or papilledema.
• Uncontrolled hyperglycemia or new‑onset diabetes mellitus in susceptible individuals.
• Rapid progression of pre‑existing malignancies due to growth factor stimulation.

When prescribing Humatrope, clinicians should evaluate patient history and monitor for conditions that may be worsened by growth hormone therapy.

• Known hypersensitivity to somatropin or any excipients.
• Active malignancy or history of cancer, as growth hormone may accelerate tumor growth.
• Uncontrolled diabetes mellitus or severe hyperglycemia.
• Intracranial lesions or increased intracranial pressure.
• Pregnancy or breastfeeding, because safety has not been established.
• Pediatric patients with closed epiphyses, where further height increase is not expected.
• Severe hepatic or renal impairment, which may affect drug clearance.

Humatrope may interact with other medicines that influence its absorption, metabolism, or physiological effects; awareness of these interactions helps optimize therapy.

Avoid

• Concomitant use of high‑dose glucocorticoids, which can antagonize growth‑hormone action.
• Simultaneous administration of insulin‑like growth factor‑1 (IGF‑1) therapy, increasing risk of hypoglycemia.
• Concurrent use of somatostatin analogs, which suppress endogenous growth hormone secretion.

Use with caution

• Oral estrogen therapy, which may reduce IGF‑1 response and require dose adjustment.
• Antidiabetic agents, as growth hormone can worsen glucose tolerance.
• Diuretics, because fluid retention from Humatrope may potentiate electrolyte shifts.
• Thyroid hormone replacement, since growth hormone can increase peripheral conversion of T4 to T3.